Case Report: Safety and Efficacy of Omalizumab in a 13-Year-Old Patient With Chronic Spontaneous Urticaria and Type 1 Diabetes

Case Report: Safety and Efficacy of Omalizumab in a 13-Year-Old Patient With Chronic Spontaneous Urticaria and Type 1 Diabetes

Chronic urticaria (CU) is defined by the presence of itchy wheals, sometimes accompanied by angioedema, lasting for at least 6 weeks. CU is treated with second-generation antihistamines, increased up to four times the normal doses for second-line treatment. Omalizumab (a monoclonal antibody anti-IgE...

Full description

Bibliographic Details
Main Authors: Paolo Del Barba, Federica Del Tedesco, Giulio Frontino, Maria Pia Guarneri, Riccardo Bonfanti, Graziano Barera
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Immunology
Subjects:
chronic spontaneous urticaria
type 1 diabetes
omalizumab
pediatrics
glycemic
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.853561/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.853561/full

Similar Items